Skip to content
OpenCapital
Get started

Dogwood Therapeutics DWTX Cash ratio

Cash ratio at other companies

Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Pfizer logo
PfizerPFE
0.1×0.0×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
1.4×+0.2×
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
0.7×+0.4×
Bioventus logo
BioventusBVS
0.2×+0.1×
Avanos Medical logo
Avanos MedicalAVNS
0.5×-0.2×

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0×0.0×
Current ratio5.9×-1.6×

Where this comes from

Calculated from Dogwood Therapeutics’s reported figures.

cash and equivalents/total current liabilities=5.2×

Based on the most recent quarter.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's cash ratio?
Dogwood Therapeutics (DWTX) reported cash ratio of 5.2× in Q1 2026.
How has Dogwood Therapeutics's cash ratio changed year-over-year?
Dogwood Therapeutics's cash ratio decreased by 24.0% year-over-year, from 6.8× to 5.2×.
What is the long-term trend for Dogwood Therapeutics's cash ratio?
Over 5 years (2020 to 2025), Dogwood Therapeutics's cash ratio has grown at a -35.7% compound annual growth rate (CAGR), from 19.5× to 2.1×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.